The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of AbbVie's 2013 sales performance.
AbbVie has shared positive top-line results from a head-to-head study of its interleukin-23 inhibitor Skyrizi (risankizumab) in Crohn's disease. ... All secondary endpoints achieved statistical significance for superiority versus Stelara, AbbVie said,
Johnson &Johnson's Stelara (ustekinumab) and Xarelto (rivaroxaban) were also listed, as well as its AbbVie-partnered Imbruvica (ibrutinib).
Johnson &Johnson's Stelara (ustekinumab) and Xarelto (rivaroxaban) are also listed, as well as its AbbVie-partnered Imbruvica (ibrutinib).
The company, along with AbbVie, Amgen, Bayer and Merck, will now co-fund the whole-genome sequencing of 250, 000 samples and have access to the resulting data for use in
AbbVie has announced that the first patient has been dosed in a late-stage study of its selective JAK inhibitor, Rinvoq (upadacitinib), in adults and adolescents with moderate-to-severe hidradenitis ... There is no cure for HS, and there are limited
No results were found
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....